Skip to main content
. 2019 Jan 31;6(2):ofz015. doi: 10.1093/ofid/ofz015

Table 1.

Characteristics of 130 HIV-Positive Participants With TB Coinfection (HIV+/TB+) and 130 HIV-Positive Matched Controls Without TB Coinfection (HIV+/TB) Selected From a Cohort of 812 ART-Naive HIV-Positive Patients Investigated for Active TBa

TB+ TB
Characteristics Included Excluded Included Excluded Total
Female 63/130 (49) 3/7 (43) 60/130 (46) 341/524 (65) 467/791 (59)
Age, years 35 (28–42) 30 (29–37) 35 (28–41) 31.5 (28–38) 32 (28–40)
CD4 count, cells/mm3 173 (94.5–271) 91 (88–197) 224 (146–328) 220 (121–327) 211 (119–320)
Hemoglobin, g/dL 10.4 (9.1–11.8) 10.9 (8.5–14.2) 12 (10.9–13.2) 11.8 (10.3–12.7) 11.6 (10.2–12.7)
HIV RNA, log10 copies/ mL 5.3 (4.7–5.6) 5.4 (5.2–5.8) 5 (4.5–5.5) 5 (5.5–5.5) 5.1 (4.5–5.6)
On TB treatment at enrollment 15/130 (12)b 0/7 (0) 0 (130) 0/524 (0) 15/791 (2)
Bacteriological results
 Sputum smear positive 29/129 (23) 2/7 (29) 0/130 0/518 (0) 31/784 (4)
 Sputum Xpert MTB/RIF positive 90/129 (70) 6/7 (86) 0/130 0/518 (0) 96/783 (12)
 Sputum culture positive 118/129 (92) 6/7 (86) 0/130 0/523 (0) 124/788 (17)
 Lymph node culture positive 4/5 (80) 0/0 (0) 0/3 (0) 0/1 (0) 4/9 (44)
Lymph node Xpert MTB/RIF positive 11/12 (92) 0 (0) 0/1 (0) 0/7 (0) 13/20 (65)
Clinical findings
 WHO-TB symptom screening positivec 120/129 (93) 6/7 (86) 101/128 (79) 398/520 (77) 625/784 (80)
 MUAC cm 21 (19.4–23) 22 (18.8–22.5) 23 (21–25) 23 (21–24.5) 22.5 (20.5–24)
 BMI kg/m2 17.7 (16.1–19.7) 17.6 (16.7–20.7) 19.5 (17.8–22) 19.1 (17.6–21.1) 19 (17.4–21)

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; MUAC, mid-upper arm circumference; RNA, ribonucleic acid; TB, tuberculosis; WHO, World Health Organization.

a

Twenty-one subjects with TB diagnosed on clinical criteria are not presented in this table. For continuous variables, median and interquartile range are presented; for categorical variables, absolute numbers and percentage of total are presented.

b

Median number of days on treatment before enrollment: 7.

c

Presence of either cough, weight loss, night sweating, or fever.